| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
REVTORPYK became commercially available on September 30th for the treatment of patients with HR+/HER2- PIK3CA wild-type locally advanced or metastatic breast cancer |
| 09 Oct 2026 |
Form 4: Furcht Leo, Director
Received 250 shares by exercise or conversion ($1.9K) |
| 05 Oct 2026 |
Form 4: Gryska David W, Director
Received 893 shares as a grant or award |
| 05 Oct 2026 |
Form 3: Gryska David W, Director
No securities owned |
| 02 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity’s Board |
| 30 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic setting |
| 26 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer |
| 18 Aug 2026 |
Form 4: Sullivan Brian F., Director
Received 80,000 shares as a grant or award · Granted 120,000 Performance Stock Units |
| 18 Aug 2026 |
Form 4: Laing Lance G., Director
Received 20,000 shares as a grant or award · Granted 10,000 Performance Stock Units |
| 18 Aug 2026 |
Form 4: Hahne Vicky, Chief Financial Officer
Received 16,000 shares as a grant or award · Granted 10,000 Performance Stock Units |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or metastatic breast cancer on July 14, 2026; on track for commercial launch late third quarter 2026 |
| 11 Aug 2026 | SCHEDULE 13G |
| 16 Jul 2026 | SCHEDULE 13G |
| 16 Jul 2026 | SCHEDULE 13D/A |
| 16 Jul 2026 |
Form 4: Baker Bros. Advisors Lp, Former 10% owner and 3 others
Sold 3,100,000 shares ($318M) |
| 15 Jul 2026 |
8-K/A: Regulation FD Disclosure; Other Events
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer |
Loading...